ALSO NOTED: Array BioPharma reaches milestone; Cytokinetics launches trial; and much more...

> Array BioPharma has reached a milestone in its collaboration with Genentech. Release

> Cytokinetics has launched a Phase I/II trial of SB-743921, a Kinesin Spindle Protein inhibitor. Release

> Schering-Plough has selected a compound identified in its collaboration with Pharmacopeia for preclinical development in metabolic disease. Release

> Dainippon Sumitomo Pharma has granted rights to the development, manufacture and marketing of Gasmotin in 10 Asian countries to Eisai. Release

And Finally… A group of plaintiffs' attorneys is offering up a package of documents outlining the case against Vioxx in exchange for 3 percent to 6 percent contingency fees. Lawyers say the package will significantly cut the cost of mounting a legal attack on Merck. Article (WSJ sub. req.)